ANSTO Publications Online >
Journal Publications >
Journal Articles >
Please use this identifier to cite or link to this item:
|Title: ||Technology evaluation: huN901-DM1 (ImmunoGen).|
|Authors: ||Smith, SV|
|Issue Date: ||25-Jul-2005|
|Publisher: ||Thomson Reuters|
|Citation: ||Smith, S. V. (2005). Technology evaluation: huN901-DM1 (ImmunoGen). Current Opinion in Molecular Therapeutics, 7(4), 394-402.|
|Abstract: ||ImmunoGen is developing huN901-DMI, a compound comprised of a CD56-targeted humanized N901 antibody conjugated to the company's proprietary cytotoxic agent. DM1, using its tumor-activated prodrug technology, for the potential treatment of cancers that express CD56, in particular, small-cell lung cancer. © 2005, Thomson Reuters|
|Appears in Collections:||Journal Articles|
Files in This Item:
There are no files associated with this item.
Items in APO are protected by copyright, with all rights reserved, unless otherwise indicated.